PI(3,5)P2

Scientists discover new causes for neurodegeneration
News-Medical-Net Sun, 28 Oct 2007 4:18 PM PDT
Diseases that cause neurons to break-down, such as Alzheimer's, Multiple Sclerosis and Creutzfeldt-Jakob disease (Mad Cow Disease), continue to be elusive to scientists and resistant to treatments.

Embryonic stem cells could be ballot issue
The Grand Rapids Press - MLive.com - Grand Rapids,MI,USA
... a difficult question: Should these tiny cell clumps be used to research cures for everything from cancer to multiple sclerosis to Parkinson's disease? ...
See all stories on this topic

Acne medicine could help MS sufferers
Canoe.ca (subscription) - Toronto,Ontario,Canada
A $4 million clinical trial begins next year to test the effectiveness of the acne drug minocycline on 200 early-stage MS patients, said Dr. Luanne Metz, ...
See all stories on this topic

Ireland's Elan sees losses reduced by strong Tysabri sales
Pharma Times (subscription) - London,UK
Net loss decreased 25% to $87.4 million, or $0.19 per share, and revenues reached $176.6 million which benefited from increased take-up of Tysabri ...
See all stories on this topic

Elan's losses narrow on MS drug sales
BusinessWeek - USA
PLC reported lower third-quarter losses Thursday and a sales milestone for its key product, the multiple sclerosis treatment Tysabri. ...
See all stories on this topic

Biogen Idec sale books not out yet, but first round bids expected ...
Financial Times - London,England,UK
The first person familiar noted that decisions pertaining to Tysabri and Rituxan, a drug targeting Non-Hodgkin's Lymphoma which Biogen has a collaborative ...
See all stories on this topic

Elan Corporation narrows Q3 pretax losses to 90.2 mln usd vs 115.6 ...
Forbes - NY,USA
Tysabri is co-marketed with US company Biogen, which has been the object of recent speculation about a possible takeover by US billionaire Carl Icahn. ...
See all stories on this topic

Elan revenues up 43% on Tysabri sales
RTE.ie - Ireland
The increase in revenues was driven mainly by the growing use of its MS drug Tysabri, which generated sales of almost $100m in the three month period. ...
See all stories on this topic